Spots Global Cancer Trial Database for fulvestrant
Every month we try and update this database with for fulvestrant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00075764 | Breast Cancer | anastrozole fulvestrant | 18 Years - | SWOG Cancer Research Network | |
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | NCT00688194 | Breast Cancer | anastrozole exemestane fulvestrant lapatinib ditos... letrozole placebo | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | NCT03939897 | Anatomic Stage ... Metastatic Brea... Metastatic HER2... Metastatic Horm... Recurrent Breas... | Abemaciclib Biopsy Biospecimen Col... Copanlisib Hydr... Diagnostic Imag... Echocardiograph... Fulvestrant Multigated Acqu... | 18 Years - | National Cancer Institute (NCI) | |
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | NCT05230810 | HER2-positive M... | Alpelisib Tucatinib Fulvestrant | 18 Years - | Criterium, Inc. | |
| Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | NCT00903006 | Breast Cancer | Fulvestrant MK-0646 Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy | NCT02569801 | Breast Cancer | Fulvestrant GDC-0810 | 18 Years - | Genentech, Inc. | |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | NCT03685331 | Metastatic Brea... Locally Advance... Advanced Breast... BRCA2 Mutation BRCA1 Mutation | Palbociclib Olaparib Fulvestrant | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | NCT01942135 | Metastatic Brea... | Palbociclib Fulvestrant Placebo Fulvestrant | 18 Years - | Pfizer | |
| A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer | NCT04191499 | Breast Cancer | Inavolisib Placebo Palbociclib Fulvestrant | 18 Years - | Hoffmann-La Roche | |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | NCT02028507 | Metastatic Brea... | Palbociclib Capecitabine Exemestane Fulvestrant | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women | NCT01300351 | Breast Cancer | Fulvestrant Placebo | 18 Years - | AstraZeneca | |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | NCT05216432 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... | RLY-2608 Fulvestrant Palbociclib 125... Ribociclib 400m... Ribociclib 600m... | 18 Years - | Relay Therapeutics, Inc. | |
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | NCT02690480 | Breast Neoplasm... | PD-0332991 (Pal... Fulvestrant Placebo | 18 Years - | Spanish Breast Cancer Research Group | |
| Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | NCT02761694 | Cancer Solid Tumors | Vevorisertib Fulvestrant Paclitaxel | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | NCT04606446 | Locally Advance... Locally Advance... Locally Advance... | PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 | 18 Years - | Pfizer | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer | NCT00274469 | Metastatic Brea... | fulvestrant anastrozole | 45 Years - 100 Years | AstraZeneca | |
| Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy | NCT04524728 | Breast Neoplasm Malign... Female | Palbociclib Letrozole 2.5mg Fulvestrant | 18 Years - | Istituti Clinici Scientifici Maugeri SpA | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | NCT03182634 | Advanced Breast... | Fulvestrant Neratinib AZD5363 Olaparib AZD6738 | 18 Years - | Institute of Cancer Research, United Kingdom | |
| The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer | NCT00065325 | Locally Advance... Metastatic Brea... | Fulvestrant Exemestane | 32 Years - 91 Years | AstraZeneca | |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg | NCT00305448 | Advanced Breast... Metastatic Brea... | Fulvestrant Fulvestrant | - | AstraZeneca | |
| The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer | NCT03768479 | Estrogen Recept... Fulvestrant | 18F-FES-PET | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | NCT06239467 | Advanced Cancer Breast Cancer | OKI-219 Fulvestrant Trastuzumab | 18 Years - | OnKure, Inc. | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04524000 | Advanced Breast... | Alpelisib Fulvestrant | 18 Years - | Novartis | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT02447328 | Locally Advance... Metastatic Brea... | Fulvestrant | 18 Years - 130 Years | AstraZeneca | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04544189 | Breast Neoplasm... | Alpelisib Fulvestrant Placebo | 18 Years - | Novartis | |
| Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | NCT02049957 | Breast Cancer | Sapanisertib Fulvestrant Exemestane | 18 Years - | Calithera Biosciences, Inc | |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg | NCT00313170 | Advanced Breast... Metastatic Brea... | Fulvestrant | 45 Years - 130 Years | AstraZeneca | |
| Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC | NCT05000736 | Hormone Recepto... | palbociclib + a... fulvestrant | 18 Years - | ChineseAMS | |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | NCT04650581 | Breast Cancer | Ipatasertib Fulvestrant Placebo | 18 Years - | Canadian Cancer Trials Group | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | NCT01142401 | Metastatic Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Bortezomib Fulvestrant Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure | NCT00570921 | Breast Cancer | Everolimus Fulvestrant | 45 Years - | University of Kentucky | |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | NCT06016738 | Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B... | Palazestrant Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Olema Pharmaceuticals, Inc. | |
| AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. | NCT00454805 | Advanced Breast... | AZD2171 Fulvestrant | 18 Years - 130 Years | AstraZeneca | |
| Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor | NCT05536128 | Advanced Breast... | Olaparib Fulvestrant | 19 Years - | Seoul National University Hospital | |
| Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. | NCT00099437 | Breast Cancer | Fulvestrant | 45 Years - 130 Years | AstraZeneca | |
| Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer | NCT04999540 | Breast Cancer | Tucidinostat Fulvestrant | 18 Years - 75 Years | Guangdong Women and Children Hospital | |
| Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China | NCT04526028 | Breast Cancer Fulvestrant Palbociclib | Fulvestrant Inj... Palbociclib | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | NCT04579380 | Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ... | tucatinib trastuzumab fulvestrant | 18 Years - | Seagen Inc. | |
| Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | NCT00903006 | Breast Cancer | Fulvestrant MK-0646 Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | NCT03344536 | Breast Cancer | Fulvestrant Debio 1347 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites | NCT01377324 | Metastatic Brea... | Diagnostic inte... | 18 Years - | University Medical Center Groningen | |
| Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer | NCT02000193 | Breast Cancer | fulvestrant | - | Sun Yat-sen University | |
| A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors | NCT02792465 | Advanced Solid ... Breast Cancer | CFI-402257 Fulvestrant | 18 Years - | University Health Network, Toronto | |
| Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites | NCT01377324 | Metastatic Brea... | Diagnostic inte... | 18 Years - | University Medical Center Groningen | |
| Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | NCT02936206 | Breast Cancer | Fulvestrant Tamoxifen | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | NCT02756364 | Breast Neoplasm... | Fulvestrant Sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy | NCT00722072 | Breast Cancer | fulvestrant sorafenib tosyl... | 18 Years - 120 Years | OHSU Knight Cancer Institute | |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | NCT04606446 | Locally Advance... Locally Advance... Locally Advance... | PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 | 18 Years - | Pfizer | |
| Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer | NCT05169567 | Breast Neoplasm Neoplasm Metast... | Abemaciclib Fulvestrant Placebo | 18 Years - | Eli Lilly and Company | |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | NCT05467891 | Locoregional Re... Hormone Recepto... HER2-negative B... | Ribociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Hoosier Cancer Research Network | |
| A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy | NCT02569801 | Breast Cancer | Fulvestrant GDC-0810 | 18 Years - | Genentech, Inc. | |
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | NCT00617188 | Ovarian Cancer | Fulvestrant | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | NCT05601440 | Breast Cancer | RP-6306 Gemcitabine Observation Niraparib Fulvestrant | - | Canadian Cancer Trials Group | |
| Fulvestrant in Treating Patients With Advanced Prostate Cancer | NCT00244998 | Prostate Cancer | fulvestrant | 18 Years - | Roswell Park Cancer Institute | |
| Second Line Breast Cancer Trial | NCT00635713 | Advanced Breast... | Fulvestrant Anastrozole Fulvestrant | 18 Years - | AstraZeneca | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT00253422 | Breast Cancer | anastrozole exemestane fulvestrant | - | National Cancer Institute (NCI) | |
| Phase II Study of Everolimus Beyond Progression | NCT02269670 | Estrogen Recept... HER2-negative B... Progesterone Re... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | everolimus anastrozole letrozole tamoxifen citra... fulvestrant megestrol aceta... | 19 Years - | Emory University | |
| Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer | NCT02530411 | Neoplasms | Fulvestrant Vandetanib | 18 Years - | Velindre NHS Trust | |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | NCT06120283 | Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ... | BGB-43395 Fulvestrant Letrozole | 18 Years - | BeiGene | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 | Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma... | Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib | - | National Cancer Institute (NCI) | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | NCT03169764 | Head and Neck S... | Avelumab Bevacizumab Capecitabine Cetuximab Cisplatin cyclophosphamid... 5-Fluorouracil ... fulvestrant leucovorin nab-paclitaxel nivolumab Lovaza Stereotactic Bo... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer | NCT01399086 | Breast Cancer | Fulvestrant | 18 Years - | Hellenic Oncology Research Group | |
| Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) | NCT05328440 | Breast Neoplasm... | Pyrotinib Malea... Dalpiciclib Ise... Inetetamab Fulvestrant | 18 Years - | Henan Cancer Hospital | |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | NCT05307705 | Breast Cancer | LOXO-783 Fulvestrant Imlunestrant Abemaciclib Anastrozole, Ex... Paclitaxel | 18 Years - | Eli Lilly and Company | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
